Compare 3M Company (MMM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Recursion Pharmaceuticals Inc — how do they compare? 3M Company trades at $164.6 (market cap $84.78B), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B). The key difference: 3M Company is far larger — about 48.7× Recursion Pharmaceuticals Inc's market cap, and 3M Company pays a 1.9% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MMM | RXRX | |
|---|---|---|
Market Cap | $84.78B | $1.74B |
Sector | Industrials | Health |
52-Week High | $183.79 | $6.79 |
52-Week Low | $141.10 | $2.84 |
Enterprise Value | $94.01B | $1.26B |
Dividend Yield | 1.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MMM trades at $167.52, down 0.62% on the day, with a bearish technical signal but strong fundamentals including a net income margin of 11.9% and consistent earnings beats. Recent news highlights strength in transportation and electronics segments, though consumer demand remains soft. The stock has gained 9.1% over the past year, supported by industrial momentum and cost management initiatives.
Outlook is mixed: analyst consensus is a Buy with a $173 price target, but high debt and valuation ratios pose risks. Near-term catalysts include Q3 2026 earnings and continued segment growth, while headwinds include cost pressures and weak consumer sales. The dividend of $0.78 per share provides income support.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
